Outcome |
Relative effect 95%CI |
LoD |
Trt. better when |
|
I2 |
k (RCT/OBS)
|
Bayesian probability
|
Overall ROB
|
Publication bias |
Degree of certainty |
Endpoint importance |
Published MA |
efficacy endpoints 00 |
deaths (OS) | 0.59 [0.44, 0.79] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | crucial | - |
deaths (OS) (extension) | 0.31 [0.14, 0.69] | | < 1 | | 0% | 1 study (1/-) | 99.8 % | NA | not evaluable | | important | - |
PFS (extension) | 0.48 [0.24, 0.96] | | < 1 | | 0% | 1 study (1/-) | 98.1 % | NA | not evaluable | | important | - |
progression or deaths (PFS) | 0.62 [0.47, 0.81] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | important | - |
objective responses (ORR) | 2.60 [1.26, 5.35] | | > 1 | | 0% | 1 study (1/-) | 99.5 % | NA | not evaluable | | non important | - |
objective responses (ORR) (extension) | 0.53 [0.19, 1.48] | | > 1 | | 0% | 1 study (1/-) | 11.4 % | NA | not evaluable | | non important | - |
safety endpoints 00 |
SAE (grade 3-4) | 0.10 [0.03, 0.33] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | non important | - |
STRAE (any grade) | 0.23 [0.11, 0.51] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | non important | - |
TRAE (any grade) | 0.22 [0.12, 0.41] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | non important | - |
TRAE (grade 3-4) | 0.06 [0.03, 0.13] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | non important | - |
TRAE leading to death (grade 5) | 0.16 [0.01, 3.24] | | < 1 | | 0% | 1 study (1/-) | 88.1 % | NA | not evaluable | | non important | - |
TRAE leading to discontinuation (any grade) | 0.28 [0.09, 0.89] | | < 1 | | 0% | 1 study (1/-) | 98.5 % | NA | not evaluable | | non important | - |
TRAE leading to discontinuation (grade 3-4) | 0.23 [0.05, 1.13] | | < 1 | | 0% | 1 study (1/-) | 96.5 % | NA | not evaluable | | non important | - |
TRAE (grade 3-4) endpoints 00 |
Abdominal pain TRAE (grade 3-4) | 0.49 [0.02, 14.75] | | < 1 | | 0% | 1 study (1/-) | 65.7 % | NA | not evaluable | | non important | - |
Alopecia TRAE (grade 3-4) | 0.49 [0.02, 14.75] | | < 1 | | 0% | 1 study (1/-) | 65.7 % | NA | not evaluable | | non important | - |
Anaemia TRAE (grade 3-4) | 0.12 [0.01, 2.29] | | < 1 | | 0% | 1 study (1/-) | 91.8 % | NA | not evaluable | | non important | - |
Arthralgia TRAE (grade 3-4) | 0.98 [0.02, 50.00] | | < 1 | | 0% | 1 study (1/-) | 50.3 % | NA | not evaluable | | non important | - |
Asthenia TRAE (grade 3-4) | 0.10 [0.01, 1.76] | | < 1 | | 0% | 1 study (1/-) | 94.1 % | NA | not evaluable | | non important | - |
Constipation TRAE (grade 3-4) | 0.98 [0.02, 50.00] | | < 1 | | 0% | 1 study (1/-) | 50.3 % | NA | not evaluable | | non important | - |
Decreased appetite TRAE (grade 3-4) | 0.98 [0.06, 15.91] | | < 1 | | 0% | 1 study (1/-) | 50.4 % | NA | not evaluable | | non important | - |
Diarrhoea TRAE (grade 3-4) | 0.16 [0.01, 3.24] | | < 1 | | 0% | 1 study (1/-) | 88.1 % | NA | not evaluable | | non important | - |
Dizziness TRAE (grade 3-4) | 0.98 [0.02, 50.00] | | < 1 | | 0% | 1 study (1/-) | 50.3 % | NA | not evaluable | | non important | - |
Fatigue TRAE (grade 3-4) | 0.09 [0.01, 0.73] | | < 1 | | 0% | 1 study (1/-) | 98.8 % | NA | not evaluable | | non important | - |
Febrile neutropenia TRAE (grade 3-4) | 0.03 [0.00, 0.58] | | < 1 | | 0% | 1 study (1/-) | 99.0 % | NA | not evaluable | | non important | - |
Leucopenia TRAE (grade 3-4) | 0.19 [0.02, 1.66] | | < 1 | | 0% | 1 study (1/-) | 93.2 % | NA | not evaluable | | non important | - |
Mucosal inflammation TRAE (grade 3-4) | 0.98 [0.02, 50.00] | | < 1 | | 0% | 1 study (1/-) | 50.3 % | NA | not evaluable | | non important | - |
Myalgia TRAE (grade 3-4) | 0.98 [0.02, 50.00] | | < 1 | | 0% | 1 study (1/-) | 50.3 % | NA | not evaluable | | non important | - |
Nausea TRAE (grade 3-4) | 0.24 [0.01, 5.45] | | < 1 | | 0% | 1 study (1/-) | 81.1 % | NA | not evaluable | | non important | - |
Neutropenia TRAE (grade 3-4) | 0.01 [0.00, 0.15] | | < 1 | | 0% | 1 study (1/-) | 99.9 % | NA | not evaluable | | non important | - |
Paraesthesia TRAE (grade 3-4) | 0.98 [0.02, 50.00] | | < 1 | | 0% | 1 study (1/-) | 50.3 % | NA | not evaluable | | non important | - |
Peripheral neuropathy TRAE (grade 3-4) | 0.16 [0.01, 3.24] | | < 1 | | 0% | 1 study (1/-) | 88.1 % | NA | not evaluable | | non important | - |
Peripheral oedema TRAE (grade 3-4) | 0.98 [0.02, 50.00] | | < 1 | | 0% | 1 study (1/-) | 50.3 % | NA | not evaluable | | non important | - |
Pneumonitis TRAE (grade 3-4) | 1.98 [0.07, 59.45] | | < 1 | | 0% | 1 study (1/-) | 34.9 % | NA | not evaluable | | non important | - |
Pyrexia TRAE (grade 3-4) | 0.49 [0.02, 14.75] | | < 1 | | 0% | 1 study (1/-) | 65.7 % | NA | not evaluable | | non important | - |
Rash TRAE (grade 3-4) | 0.24 [0.01, 5.45] | | < 1 | | 0% | 1 study (1/-) | 81.1 % | NA | not evaluable | | non important | - |
Vomiting TRAE (grade 3-4) | 0.49 [0.02, 14.75] | | < 1 | | 0% | 1 study (1/-) | 65.7 % | NA | not evaluable | | non important | - |